ClinicalTrials.gov
public full text
Public Domain
A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
The purpose of this study is to understand the safety profile of LY2181308 sodium administered in combination with idarubicin and cytarabine to patients with relapsed or refractory acute myeloid leukemia (AML).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Addition of Hydroxyurea to Fludarabine, Cytarabine, Idarubicin and Venetoclax Salvage Therapy for Adults With Relapsed or Refractory Acute Myeloid Leukemia#1044331
- Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia#839290
- LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy#1171408
- A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia#855877
- Timed-Sequential Induction in CBF-AML#1095956
Record · ID 1075080
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive